

ID Design 2012/DOEL Skopje, Republic of Macedonia  
 South East European Journal of Immunology  
 Volume 2016; Article ID 20009, 5 pages  
<http://dx.doi.org/10.3889/seejim.2016.20009>  
 eISSN: 1857-9388  
**Basic Immunology**



# CD56<sup>dim</sup>/CD56<sup>bright</sup> NK Cell Subpopulations and CD16/CD57 Expression Correlated with Tumor Development Stages

Cornel Ursaciuc<sup>1\*</sup>, Mihaela Surcel<sup>1</sup>, Radu Huică<sup>1</sup>, Dan Ciotaru<sup>1</sup>, Maria Dobre<sup>1</sup>, Ioana Ruxandra Pirvu<sup>1</sup>, Ciprian Cirimbei<sup>2</sup>, Dan Mischianu<sup>3</sup>, Ovidiu Bratu<sup>3</sup>, Gheorghita Isvoranu<sup>1</sup>, Eugen Brătucu<sup>2</sup>

<sup>1</sup>“Victor Babeș” National Institute of Pathology, Immunology Department, Bucharest, Romania; <sup>2</sup>“Carol Davila” University of Medicine and Pharmacy, Surgical Oncology Department, Bucharest, Romania; <sup>3</sup>Military University Emergency Hospital, Urology Department, Bucharest, Romania

## Abstract

**Citation:** Ursaciuc C, Surcel M, Huică R, Ciotaru D, Dobre M, Pirvu IR, Cirimbei C, Mischianu D, Bratu O, Isvoranu G, Brătucu E. CD56<sup>dim</sup>/CD56<sup>bright</sup> NK Cell Subpopulations and CD16/CD57 Expression Correlated with Tumor Development Stages. *SEE J Immunol.* 2016 May 28; 2016:20009. <http://dx.doi.org/10.3889/seejim.2016.20009>

**Keywords:** NK cells; NK-CD56<sup>dim</sup>; NK-CD56<sup>bright</sup>; CD16; CD57; tumor development.

**\*Correspondence:** Cornel Ursaciuc. “Victor Babeș” National Institute of Pathology, Immunology Department, Bucharest, Romania. Tel: +40-21-3192732. Fax: +40-21-3194528 Email: [imunop@vbabes.ro](mailto:imunop@vbabes.ro)

**Received:** 29-Mar-2016; **Revised:** 03-May-2016; **Accepted:** 09-May-2016; **Published:** 28-May-2016

**Copyright:** © 2016 Cornel Ursaciuc, Mihaela Surcel, Radu Huică, Dan Ciotaru, Maria Dobre, Ioana Ruxandra Pirvu, Ciprian Cirimbei, Dan Mischianu, Ovidiu Bratu, Gheorghita Isvoranu, Eugen Brătucu. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Competing Interests:** The authors have declared that no competing interests exist.

**BACKGROUND:** NK cells are characterized by cytotoxic activity against tumor cells and CD3-CD16+CD56+ phenotype. Two distinct subpopulations of NK cells were characterized in the peripheral blood: NK-CD56<sup>dim</sup> representing over 95% of NK cells and involved in antitumor cytotoxicity, and NK-CD56<sup>bright</sup> representing approximately 10% of NK cells and involved in secretion of cytokines.

**AIM:** The aim of the study was to compare the presence of NK-CD56<sup>dim</sup>/NK-CD56<sup>bright</sup> subpopulations and their CD16/CD57 expression in peripheral blood NK cells during the particular development stages of malignancy: primary tumor (PT), lymph node invasion (LNI) and distant sites metastases (Mt).

**MATERIAL AND METHODS:** We have analyzed by flow-cytometry peripheral blood samples from total 36 cancer patients: 24 patients with PT, 6 patients with LNI and 6 patients with Mt.

**RESULTS:** The presence of the overall NK cells showed no significant variation between patients in different stages of tumor development. The phenotype analysis showed that CD16+ and/or CD57+ cells were lower in LNI patients compared to PT or Mt patients. Double-positive CD16+CD57+ cells were found decreased in patients with Mt, compared to patients with PT. During the stages of tumor development, NK-CD56<sup>bright</sup> subpopulation increased progressively (7% in PT patients, 13% in LNI patients, 65% in Mt patients), whereas NK-CD56<sup>dim</sup> subpopulation gradually decreased (92%, 86%, and 35% respectively). CD16/CD57 expression decreased in NK-CD56<sup>dim</sup> and increased in NK-CD56<sup>bright</sup> cells over the three studied stages.

**CONCLUSION:** Our results show changes in NK cells characteristics during tumor development: reversal of NK-CD56<sup>dim</sup>/NK-CD56<sup>bright</sup> distribution and modification of CD16/CD57 expression. Both types of changes can concur in reducing the efficiency of NK cell activity in patients with progressive tumors.

## Introduction

NK cells are characterized as large granular lymphocytes with the CD3<sup>+</sup>CD16<sup>+</sup>CD56<sup>+</sup> phenotype [1-3] and antitumor cytotoxic activity [4-7]. Other molecules associated with these cells have been described, such as adhesion molecule CD57, cytotoxicity receptors KIR (CD158), LIR (CD85), NKG2 (CD94, CD315) and NKP (CD335, CD336) [8-11]. During the last decade, two distinct subpopulations of NK cells were characterized as having primary phenotypic expression associated with

a specific function: NK-CD56<sup>dim</sup> (CD56<sup>dim/neg</sup>, CD56<sup>low</sup>) and NK-CD56<sup>bright</sup> (CD56<sup>high</sup>) [12-14]. NK-CD56<sup>dim</sup> cells comprise the majority of peripheral blood and spleen NK cells (> 95%), they have CD16<sup>+/+</sup>CD57<sup>-</sup>KIR<sup>+</sup>NKP<sup>+</sup> phenotype and are involved in antitumor cytotoxicity [15, 16]. NK-CD56<sup>bright</sup> cells represent approximately 10% of all NK cells, are mainly located in the lymph nodes and tonsils, express predominantly CD16<sup>+/+</sup>CD57<sup>-</sup>KIR<sup>-</sup> phenotype, lacking cytotoxicity receptors but are involved in the active secretion of cytokines [17-19].

The particular distribution of NK subpopulations can be significant and suggestive

when evaluating their cytotoxic potency as vigorous antitumor cellular immune response players. Some deficiencies in the function of tumor-infiltrating NK cells have been observed [20-22], showing that the tumor microenvironment may play an important role in the development of NK cytotoxicity. However, a relationship between the intratumoral NK cell functions and NK-CD56<sup>dim</sup>/NK-CD56<sup>bright</sup> subsets could not be clearly established. In contrast, significant features were recently discovered by investigating the distribution of NK blood subsets. The reported results indicate that predominance of peripheral CD56<sup>dim</sup>CD16<sup>+</sup>KIR<sup>+</sup> NK cells constitutes an end result of the recruitment of NK-CD56<sup>bright</sup>CD16<sup>-</sup>KIR<sup>-</sup> in the local immune response [23]. This phenomenon seems to be facilitated by chemokines [24] and upon IL-2, IL-12 or IL-15 stimulation [25]. Although some particular aspects of NK subpopulations distribution in the peripheral blood have been already observed in viral diseases [26, 27], pregnancy [28, 29] and even in autoimmune diseases [30], data regarding their value in the diagnosis of cancer are scarce.

Based on our preliminary studies [31], we now attempt to compare different aspects of the phenotype and peripheral NK cell subpopulations along the three progressive stages of tumor development: primary tumor (PT), lymph node invasion (LNI), metastases (Mt). We consider that, among other features, the diagnosis and monitoring of tumor development depend on the assessment of changes in the distribution of NK cells.

## Materials and Methods

### Patients

Whole peripheral blood samples were collected from 36 cancer patients (24 patients with PT, 6 patients with LNI and 6 patients with Mt). All subjects gave informed consent before their inclusion in the study.

PTs were 10 retroperitoneal, 2 kidney, 2 bladder, 4 colons, 2 gastric, 2 breasts, 1 ovarian, 1 pelvis. There were 11 man and 13 women, average age 62. The patients with LNI had either osteosarcoma, breast, squama cellular, colon, renal and perineal tumor. There were 4 man and 2 women, average age 63. Mt came from 3 colorectal, 1 gastric, 1 breast and 1 retroperitoneal carcinoma. There were 4 man and 2 women, average age 65.

No patient supported immunomodulatory treatment at the moment of testing. Blood samples from 10 healthy donors served as controls.

The study was approved by the institution ethics committee.

## Lymphocyte immunophenotyping

All patients and control subjects were tested for lymphocyte populations (T, B and NK cells) by flow cytometry immunophenotyping at FACSCalibur cytometer (BD Biosciences, San Jose, CA, USA), using 4-colour automatic methodology. The blood was processed with MultiTest IMK Kit (BD Biosciences) according to manufacturer's instructions. Data acquisition was performed using BD MultiSet software.

## Characterization of NK cells

Given that MultiTest immunophenotyping kit evaluates only CD16<sup>+</sup> NK cells subset, we performed an additional analysis of NK cell phenotype by assessing CD16/CD57 expression and CD56<sup>dim</sup>/CD56<sup>bright</sup> subpopulations. The analysis was performed in 8 patients with PT and all patients with LNI and Mt. The peripheral blood samples were labeled with CD3PerCP, CD56APC, CD16PE and CD57FITC (BD Biosciences) and then phenotyped at FACSCalibur cytometer by the 4-color manual method, using BD CellQuest software for data acquisition (Figure 1). All monoclonal antibodies were used according to manufacturer's instructions as previously described [32].




Figure 1: Flow cytometric dot plot analysis of NK cell subsets. The determination with BD FACSCalibur cytometer by manual 4-color method, data acquisition with BD CellQuest software. a: CD3<sup>-</sup> cells of total lymphocytes, b: CD3<sup>+</sup>CD56<sup>+</sup> cells (NK cells), c: NK-CD56<sup>dim</sup> and NK-CD56<sup>bright</sup> subpopulations in CD3<sup>+</sup>CD56<sup>+</sup> cells, d: CD16<sup>+</sup> phenotype in NK cell subpopulations, e: CD57<sup>+</sup> phenotype in the NK cell subpopulations

## Statistical analysis

The results are presented as the mean  $\pm$  standard deviation of cell percentages.

The T, B and NK cells were measured as a percentage of total lymphocytes. Normal ranges are 5<sup>th</sup> to 95<sup>th</sup> percentile, as stated in Table 1.

NK subpopulations and cell phenotypes were calculated as percentages of total CD56<sup>+</sup> cells.

Graphs and t-test were performed using Microsoft Excel software.

## Results

### Lymphocyte immunophenotyping

The populations of peripheral blood lymphocytes revealed some differences in the distribution of cells between the three stages of tumor development (Table 1). Thus, CD4<sup>+</sup> T-cells and B cells were higher in patients with PTs compared to the level observed in patients with Mt. CD8<sup>+</sup> T cells were higher in patients with Mt, compared to the patients with PT. In addition, T-CD4<sup>+</sup>: T-CD8<sup>+</sup> ratio was lower in LNI and Mt patients than in patients with PTs.

**Table 1: Lymphocyte percentages in peripheral blood of tested subjects**

Cells	Controls	PT patients	LNI patients	Mt patients	Normal range
T-CD3 <sup>+</sup>	69 ± 6	67 ± 13	78 ± 11	70 ± 12	56 – 86
T-CD4 <sup>+</sup>	41 ± 5	40 ± 11	40 ± 9	34 ± 6 <sup>****</sup>	33 – 57
T-CD8 <sup>+</sup>	28 ± 7	26 ± 14	36 ± 9	36 ± 12 <sup>***</sup>	13 – 39
T-CD4 <sup>+</sup> :T-CD8 <sup>+</sup> ratio	1.6 ± 0.4	2.0 ± 1.0	1.2 ± 0.5 <sup>***</sup>	1.0 ± 0.3 <sup>*</sup>	1.5 – 2.5
B	13 ± 3	12 ± 5	6 ± 3 <sup>*</sup>	9 ± 3 <sup>**</sup>	6 – 22
NK	16 ± 5	19 ± 14	16 ± 13	21 ± 11	5 – 25

<sup>a</sup> 5<sup>th</sup> to 95<sup>th</sup> percentile, as presented by MultiTest IMK Kit manufacturer; <sup>\*</sup> p < 0.001 compared to PT patients; <sup>\*\*</sup> p < 0.01 compared to PT patients; <sup>\*\*\*</sup> p < 0.02 compared to PT patients; <sup>\*\*\*\*</sup> p < 0.05 compared to PT patients.

The distribution of NK cells did not show any significant variation between control subjects and patients with PTs. Also, no significant imbalance has been observed during the stages of tumor development in terms of percentage of NK cells.

### Characterization of NK cells

#### a. CD16/CD57 expression

Total NK cells (CD56<sup>+</sup>) were further examined to determine CD16<sup>+</sup> or CD57<sup>+</sup> phenotype (single-positive cells) and CD16<sup>+</sup>CD57<sup>+</sup> phenotype (double-positive cells). The results are shown in Table 2.

Irrespective of CD16<sup>+</sup> or CD57<sup>+</sup> phenotype, the percentages of single- or double-positive cells were the lowest in patients with LNI as compared to controls or PT and Mt patients. As considering the three tumor development stages, the percentages of single- or double-positive cells were significantly higher in patients with PT, with no significant difference when comparing to controls.


**Table 2: NK cell phenotypes during tumor development stages**

	NK cell phenotypes (% cells)			
	CD56 <sup>+</sup> <sup>a</sup>	CD56 <sup>+</sup> CD16 <sup>+</sup> <sup>b</sup>	CD56 <sup>+</sup> CD57 <sup>+</sup> <sup>b</sup>	CD56 <sup>+</sup> CD57 <sup>+</sup> CD16 <sup>+</sup> <sup>b</sup>
Controls	15 ± 6	93 ± 5	53 ± 13	52 ± 12
PT patients	16 ± 12	86 ± 11	71 ± 17	65 ± 19
LNI patients	10 ± 4	39 ± 28 <sup>*</sup>	36 ± 18 <sup>**</sup>	20 ± 18 <sup>*</sup>
Mt patients	26 ± 10	51 ± 17 <sup>**</sup>	64 ± 12 <sup>***</sup>	49 ± 18

<sup>a</sup> Percentage in all lymphocytes; <sup>b</sup> Percentage in CD56<sup>+</sup> cells; <sup>\*</sup> p < 0.001 compared to PT patients and controls; <sup>\*\*</sup> p < 0.01 compared to PT patients; <sup>\*\*\*</sup> p < 0.05 compared to PT patients.

#### b. CD56<sup>dim</sup>/CD56<sup>bright</sup> subpopulations


During the stages of tumor development, the distribution of NK-CD56<sup>dim</sup>/NK-CD56<sup>bright</sup> subpopulations changed gradually (Figure 2). The patients with PT showed a similar distribution with the control subjects, i.e. NK-CD56<sup>dim</sup> was the predominant subpopulation (93%). The percentage of NK-CD56<sup>bright</sup> subpopulation gradually increased from 7% in patients with PT to 13% in patients with LNI and 65% in patients with Mt (p < 0.001), while NK-CD56<sup>dim</sup> subpopulation was decreasing.



**Figure 2: Changes in the distribution of NK-CD56<sup>dim</sup>/NK-CD56<sup>bright</sup> subpopulations according to the period of tumor development**

NK-CD56<sup>dim</sup>/NK-CD56<sup>bright</sup> subpopulations showed similar variation as above in terms of CD16/CD57 phenotypes (Figure 3). In NK-CD56<sup>dim</sup> subpopulation, CD16<sup>+</sup>/CD57<sup>+</sup> expression progressively decreased as follows: CD16<sup>+</sup> cells from 89 ± 12% in PT patients to 11 ± 9% in Mt patients; CD57<sup>+</sup> cells from 73 ± 16 % in PT patients to 10 ± 6% in Mt patients; CD16<sup>+</sup>CD57<sup>+</sup> cells from 68 ± 19% in PT patients to 7 ± 8% in Mt patients (Figure 3a).

In NK-CD56<sup>bright</sup> subpopulation, the CD16<sup>+</sup>/CD57<sup>+</sup> expression progressively increased as follows: CD16<sup>+</sup> cells from 40 ± 33% in PT patients to 91 ± 8% in Mt patients; CD57<sup>+</sup> cells from 28 ± 30% in PT patients to 71 ± 20% in Mt patients; CD16<sup>+</sup>CD57<sup>+</sup> cells from 28 ± 30% in PT patients to 70 ± 20% in Mt patients (Figure 3b).



**Figure 3: CD16/CD57 phenotypes in NK subpopulations during tumor stages. a: Changes in the phenotype of NK-CD56<sup>dim</sup> subpopulation, b: Changes in the phenotype of an NK-CD56<sup>bright</sup> subpopulation**

It must be emphasized that the values are not statistically significant because the three groups did not include the same patients. However, they could highlight a possible trend in expression of CD16/CD57 markers along the evolutionary phases of the tumor.

## Discussion

We have focused on assessing the NK cell population in terms of its representation during the progressive stages of malignancy, from primary tumors, lymph nodes involvement to distant sites metastasis (PT, LNI, Mt). It is known that NK cells are actively involved in the anti-tumoral response, hence, we wanted to evaluate NK cell phenotype and their subpopulations distribution in the peripheral blood as possible indicators of tumor development to more advanced stages. At the same time, evaluating the specific phenotype in relation to tumor evolution, new markers indicating antitumor cellular cytotoxicity could be revealed. We have purposely chosen different solid cancers to highlight that stages of tumor development can have common immune-related mechanisms, possibly sustained by a clear anti-tumoral cell like NK population.

The above-mentioned stages of tumor progression we considered were mainly clinical, concerning that they were diagnosed by standard clinical/paraclinical methods. Therefore, an auxiliary method as the determination of NK cells supplies additional information, indicating how the tumor growth and evolution affect these cells. This could be important since the non-surgical anti-tumor therapy may target for specific NK activity improvement [22].

The percentages of peripheral blood NK cells varied slightly in patients at different stages of tumor development. In spite of this minor variation, other data can be provided by analyzing the expression of CD16 and CD57 molecules or distribution of NK-CD56<sup>dim</sup>/NK-CD56<sup>bright</sup> subsets. Although functional differences between the two NK subpopulations are well known [15, 17], relatively little evidence was provided about their participation in specific antitumor response and their possible assessment during tumor development.

We also have observed two changes in NK subpopulations during tumor evolution: a downward trend in the share of NK-CD56<sup>dim</sup> subpopulation and on the other hand a progressive increase of NK-CD56<sup>bright</sup> subpopulation. Taking into account that NK-CD56<sup>dim</sup> cells exert largely cytotoxic actions, we assume that tumor progression could be favored by the decrease of this subpopulation. Given that the increased NK-CD56<sup>bright</sup> cells develop regulatory activities, it can be concluded that they are not very effective in the recruitment of other active cytotoxic cells, such as CD8<sup>+</sup> T cells, which are essential to the eradication of metastatic tumors [33]. Even if we found significantly increased peripheral blood CD8<sup>+</sup> T cells in patients with Mt compared to PT patients, it is doubtful whether these cytotoxic cells are capable of working effectively. For this reason, we tend to assume that changing the NK-CD56<sup>dim</sup>/NK-CD56<sup>bright</sup> balance in favor of NK-CD56<sup>bright</sup> cells may represent probably a warning sign

for tumor escape.

Examining the CD16/CD57 phenotype, we observed that the percentages of positive NK cells were significantly lower in patients with LNI compared to the levels observed in PT or Mt patients. Knowing that both CD16 and CD57 molecules are involved in intercellular interactions, we can emphasize that this decrease could be an issue in NK cell adhesion during tumor growth, especially in the lymph node invasion process, which seems to be a critical moment. This phenomenon may be exacerbated by the lower NK-CD56<sup>dim</sup> subpopulation with decreased CD16/CD57 expression and cannot be corrected by the increase of NK-CD56<sup>bright</sup> subset. Thus, such a hypothetical replacement of a cytotoxic subpopulation (NK-CD56<sup>dim</sup>) with a regulatory subpopulation (NK-CD56<sup>bright</sup>) cannot be beneficial in terms of cytotoxicity efficiency and anti-tumoral effect [5].

Our presented results pinpoint an ineffective change of the peripheral blood NK cells during tumorigenesis and tumor dynamics: gradual decrease of the NK-CD56<sup>dim</sup> and increase of the NK-CD56<sup>bright</sup> subpopulations. This could favor tumor invasion in the lymph nodes, ending with a reversal of the NK-CD56<sup>dim</sup>/NK-CD56<sup>bright</sup> distribution in the course of metastasis process. Changing in CD16/CD57 co-expression on NK cells can cause difficulties in efficient cytotoxicity by reducing the intercellular contact, a critical step in developing an anti-tumoral effect. Each of these changes contributes to the ineffectiveness of NK cells and hence tumor progression. These features can be sensed indirectly by phenotypic characterization of NK cells and their subpopulations and could be cellular markers of poor clinical outcome in solid tumors.

## Acknowledgements

This work was supported by grant PN2 41-046/2007 of the Romanian Ministry of Education and Research. The authors thank Monica Neagu ("Victor Babeş" Institute, Bucharest) for revising the manuscript and criticism.

## References

- Whiteside TL, Herberman RB. The role of human natural killer cells in health and disease. *Clin Diagn Lab Immunol*. 1994;1:125-33. PMID:7496932 PMCid:PMC368214
- Caligiuri MA. Human natural killer cells. *Blood*. 2008;112:461-9. <http://dx.doi.org/10.1182/blood-2007-09-077438> PMID:18650461 PMCid:PMC2481557
- Fan YY, Yang BY, Wu CY. Phenotypically and functionally distinct subsets of natural killer cells in human PBMCs. *Cell Biol Int*. 2008;32:188-97. <http://dx.doi.org/10.1016/j.cellbi.2007.08.025> PMID:17920947
- Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or adaptive immunity? The

- example of natural killer cells. *Science*. 2011;331:44-9. <http://dx.doi.org/10.1126/science.1198687> PMID:21212348 PMCID:PMC3089969
5. Levy EM, Roberti MP, Mordoh J. Natural killer cells in human cancer: from biological functions to clinical applications. *J Biomed Biotechnol*. 2011;2011:676198. <http://dx.doi.org/10.1155/2011/676198> PMID:21541191 PMCID:PMC3085499
6. De Saint Basile G, Ménasché G, Fischer A. Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules. *Nat Rev Immunol*. 2010;10:568-79. <http://dx.doi.org/10.1038/nri2803> PMID:20634814
7. Dustin ML, Long EO. Cytotoxic immunological synapses. *Immunol Rev*. 2010;235:24-34. <http://dx.doi.org/10.1111/j.0105-2896.2010.00904.x> PMID:20536553 PMCID:PMC2950621
8. Schönberg K, Fischer JC, Kögler G, Uhrberg M. Neonatal NK-cell repertoires are functionally, but not structurally, biased toward recognition of self HLA class I. *Blood*. 2011;117:5152-6. <http://dx.doi.org/10.1182/blood-2011-02-334441> PMID:21415265
9. Lopez-Vergès S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H, Norris PJ, Nixon DF, Lanier LL. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. *Blood*. 2010;116:3865-74. <http://dx.doi.org/10.1182/blood-2010-04-282301> PMID:20733159 PMCID:PMC2981540
10. Romero AI, Thoren FB, Brune M, Hellstrand K. NKp46 and NKG2D receptor expression in NK cells with CD56dim and CD56bright phenotype: regulation by histamine and reactive oxygen species. *Br J Haematol*. 2005;132:91-8. <http://dx.doi.org/10.1111/j.1365-2141.2005.05842.x> PMID:16371024
11. Maltseva DV, Sakharov DA, Tonevitsky EA, Northoff H, Tonevitsky AG. Killer cell immunoglobulin-like receptors and exercise. *Exerc Immunol Rev*. 2011;17:150-63. PMID:21446357
12. Wendt K, Wilk E, Buyny S, Buer J, Schmidt RE, Jacobs R. Gene and protein characteristics reflect functional diversity of CD56dim and CD56bright NK cells. *J Leukoc Biol*. 2006;80:1529-41. <http://dx.doi.org/10.1189/jlb.0306191> PMID:16966385
13. Takahashi E, Kuranaga N, Satoh K, Habu Y, Shinomiya N, Asano T, Seki S, Hayakawa M. Induction of CD16+ CD56bright NK cells with antitumor cytotoxicity not only from CD16- CD56bright NK cells but also from CD16- CD56dim NK cells. *Scand J Immunol*. 2007;65:126-38. <http://dx.doi.org/10.1111/j.1365-3083.2006.01883.x> PMID:17257217
14. Yu J, Mao HC, Wei M, Hughes T, Zhang J, Park I, Liu S, McClory S, Marcucci G, Trotta R, Caligiuri MA. CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. *Blood*. 2010;115:274-81. <http://dx.doi.org/10.1182/blood-2009-04-215491> PMID:19897577 PMCID:PMC2808153
15. Moretta L. Dissecting CD56dim human NK cells. *Blood*. 2010;116:3689-91. <http://dx.doi.org/10.1182/blood-2010-09-303057> PMID:21071612
16. Beziat V, Descours B, Parizot C, Debre P, Vieillard V. NK cell terminal differentiation: correlated stepwise decrease of NKG2A and acquisition of KIRs. *PLoS One*. 2010;5:e11966. <http://dx.doi.org/10.1371/journal.pone.0011966> PMID:20700504 PMCID:PMC2917352
17. Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, Caligiuri MA. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. *Blood*. 2003;101:3052-7. <http://dx.doi.org/10.1182/blood-2002-09-2876> PMID:12480696
18. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA. Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset. *Blood*. 2001;97:3146-51. <http://dx.doi.org/10.1182/blood.V97.10.3146> PMID:11342442
19. Poli A, Michel T, Theresine M, Andres E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. *Immunology*. 2009;126:458-65. <http://dx.doi.org/10.1111/j.1365-2567.2008.03027.x> PMID:19278419 PMCID:PMC2673358
20. Shunyakov L, Ryan CK, Sahasrabudhe DM, Khorana AA. The Influence of host response on colorectal cancer prognosis. *Clin Colorectal Cancer*. 2004;4:38-45. <http://dx.doi.org/10.3816/CCC.2004.n.008> PMID:15207019
21. Stojanovic A, Cerwenka A. Natural killer cells and solid tumors. *J Innate Immun*. 2011;3:355-64. <http://dx.doi.org/10.1159/000325465> PMID:21502747
22. Subleski JJ, Wiltrot RH, Weiss JM. Application of tissue-specific NK and NKT cell activity for tumor immunotherapy. *J Autoimmun*. 2009;33:275-81. <http://dx.doi.org/10.1016/j.jaut.2009.07.010> PMID:19682859 PMCID:PMC2783592
23. Parolini S, Santoro A, Marcenaro E, Luini W, Massardi L, Facchetti F, Communi D, Parmentier M, Majorana A, Sironi M, Tabellini G, Moretta S, Sozzani S. The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. *Blood*. 2007;109:3625-32. <http://dx.doi.org/10.1182/blood-2006-08-038844> PMID:17202316
24. Romagnani C, Juelke K, Falco M, Morandi B, D'Agostino A, Costa R, Ratto G, Forte G, Carrega P, Lui G, Conte R, Strowig T, Moretta A, Munz C, Thiel A, Moretta L, Ferlazzo G. CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. *J Immunol*. 2007;178:4947-55. <http://dx.doi.org/10.4049/jimmunol.178.8.4947> PMID:17404276
25. Moretta A, Marcenaro E, Parolini S, Ferlazzo G, Moretta L. NK cells at the interface between innate and adaptive immunity. *Cell Death Diff*. 2008;15:226-33. <http://dx.doi.org/10.1038/sj.cdd.4402170> PMID:17541426
26. Miyagi T, Shimizu S, Tatsumi T, Nishio K, Hiramatsu N, Kanto T, Hayashi N, Takehara T. Differential alteration of CD56bright and CD56dim natural killer cells in frequency, phenotype and cytokine response in chronic hepatitis C virus infection. *J Gastroenterol*. 2011;46:1020-30. <http://dx.doi.org/10.1007/s00535-011-0408-8> PMID:21559771
27. Alter G, Altfeld M. NK cells in HIV-1 infection: evidence for their role in the control of HIV-1 infection. *J Int Med*. 2008;265:29-42. <http://dx.doi.org/10.1111/j.1365-2796.2008.02045.x> PMID:19093958 PMCID:PMC2842208
28. Kwak-Kim J, Cheol Park J, Kyong Ahn H, Woo Kim J, Gilman-Sachs A. Immunological modes of pregnancy loss. *Am J Reprod Immunol*. 2010;63:611-23. <http://dx.doi.org/10.1111/j.1600-0897.2010.00847.x> PMID:20367626
29. Djulejic E, Petlichkovski A, Trajkov D, Dimitrov G, Alabakovska S. KIR gene frequencies in women with infertility problems. *SEE J Immunol*. 2015; 2015:20002. <http://dx.doi.org/10.3889/seejim.2015.20002>
30. Schleinitz N, Vely F, Harle J-R, Vivier E. Natural killer cells in human autoimmune diseases. *Immunology*. 2010;131:451-8. <http://dx.doi.org/10.1111/j.1365-2567.2010.03360.x> PMID:21039469 PMCID:PMC2999796
31. Surcel M, Huică R, Ciotaru D, Dobre M, Isvoranu G, Belmege A, Pîrvu I, Ursaciuc C. Relation between NK cells subpopulations and tetraspanin membrane expression in malignant tumors. In: Schmidt RE (Eds.) 2nd European Congress of Immunology – ECI. Monduzzi Editore, Italy, 2009: 77-81.
32. Ursaciuc C, Surcel M, Ciotaru D, Dobre M, Pîrvu IR, Munteanu AN, Alecu M, Huica R. Regulatory T cells and TH1/TH2 cytokines as immunodiagnosis keys in systemic autoimmune diseases. *Rom Arch Microbiol Immunol*. 2010;69:79-84. PMID:21235134
33. Gu T, Kilinc MO, Egilmez NK. Transient activation of tumor-associated T-eVector/memory cells promotes tumor eradication via NK-cell recruitment: minimal role for long-term T-cell immunity in cure of metastatic disease. *Cancer Immunol Immunother*. 2008;57:997-1005. <http://dx.doi.org/10.1007/s00262-007-0430-0> PMID:18049819